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Abstract
Various types of cerebrovascular diseases can result in epilepsy in any age, 
especially in the elderly. Besides well-known cause of epilepsy as large cerebral 
infarction involving cerebral cortex and intracerebral hemorrhage, there are 
growing evidences of roles of subcortical infarction, chronic subdural hematoma, 
and superficial siderosis of the central nervous system in the pathogenesis of 
epilepsy. We review here the epidemiology and possible predictors of epilepsy in 
each type of cerebrovascular lesions and summarize the characteristics of semiol-
ogy and electroencephalography findings in order to take early treatment strategy. 
Additionally, relevance of acute-symptomatic seizures and status epilepticus to 
epilepsy is discussed.
Keywords: epilepsy, cerebrovascular diseases, cerebral infarction, intracranial 
hemorrhage, stroke, provoked seizures, acute symptomatic seizures, early seizures, 
late seizures
1. Introduction
Various kinds of brain insults are associated with an increased risk for develop-
ment of seizures and epilepsy. In adults, a probable etiology of approximately 50% 
of new-onset seizures can be determined. Cerebrovascular diseases are the most 
common risk factors of epilepsy (21%), followed by tumors (11%) and traumatic 
brain injury (7%) [1]. In children and adolescents of 0–19 years of age, the leading 
epilepsy etiologies are static encephalopathies (38.2%), stroke (12.1%), traumatic 
brain injury (11.4%), and infection (8.6%) [2].
The traditional definition of stroke is based on clinical characteristics of the 
sudden onset of loss of focal neurological dysfunction due to infarction or hemor-
rhage in the relevant part of the brain, retina, or spinal cord, lasting longer than 
24 hours [3]. Stroke is classified into cerebral infarction, intracerebral hemorrhage, 
and subarachnoid hemorrhage (SAH).
Post-stroke seizures have been classified as either early seizures or late seizures, 
depending on the interval from stroke onset to seizure onset. In the field of stroke, 
the latent period of two weeks has been most commonly used to distinguish 
between early seizures and late seizures [4]. Approximately 5–10% of patients 
with stroke present early seizures within the first two weeks and about half of 
them occur during the first day after the stroke [5, 6]. In the field of epilepsy, the 
International League Against Epilepsy (ILAE) proposes a recommendation to define 
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acute symptomatic seizures as seizures occurring within one week subsequent to 
acute damage to the brain, caused by such as stroke, traumatic brain injury, anoxic 
encephalopathy, and intracranial surgery [7]. Seizures occurring at least two weeks 
after stroke are called late or remote symptomatic seizures [4, 8]. Epilepsy is a brain 
disorder with an enduring preposition to generate epileptic seizures, usually appli-
cable to patients having two or more unprovoked seizures occurring at least 24 hours 
apart. In addition, ILAE updated the practical definition of epilepsy in 2014 to apply 
also to a condition of one unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after two unpro-
voked seizures, occurring over the next 10 years [9]. Therefore, occurrence of an 
unprovoked late seizure is necessary and sufficient for the diagnosis of post-stroke 
epilepsy (PSE) because of a high risk of recurrence; such patients are recommended 
to be treated with antiepileptic medication under the diagnosis of epilepsy [9].
Depending on the type of underlying cerebrovascular disease, 3–30% of patients 
who experience stroke may develop PSE [10]. The risk to develop epilepsy after 
stroke is the highest during the first two years, but still elevated even 10 years after 
stroke [11].
Status epilepticus is a medical emergency that has high mortality rate (approxi-
mately 20%) [12]. Classically status epilepticus was defined as a condition char-
acterized by an epileptic seizure sufficiently prolonged or repeated at sufficiently 
brief intervals so as to produce an unvarying and enduring epileptic condition. 
In 2015, ILAE proposed the new definition of status epilepticus as follows. Status 
epilepticus is a condition resulting either from the failure of the mechanisms 
responsible for seizure termination or from the initiation of mechanisms, which 
lead to abnormally, prolonged seizures (after time point t1). It is a condition, which 
can have long-term consequences (after time point t2), including neuronal death, 
neuronal injury, and alteration of neuronal networks, depending on the type and 
duration of seizures. Because of incomplete evidence, each time point should be 
considered as the best estimates currently available. In the case of convulsive status 
epilepticus, t1 at 5 minute and t2 at 30 minutes are suggested based on animal 
experiments and clinical research [13]. Patients with status epilepticus rarely 
recover spontaneously; therefore they should be treated with antiepileptic drugs as 
soon as possible.
Status epilepticus occurs in 1.5–2.8% of stroke patients [14, 15]. In the older 
adults (≧65 years of age), 52.3% of status epilepticus are caused by stroke [16]. 
In the older adults (≧60 years of age), semiology of status epilepticus is less fre-
quently generalized tonic–clonic seizures compared to younger adults (33% vs. 
63%, p = 0.001); on the other side, non-convulsive status epilepticus with coma are 
exclusively seen in older patients (10.3% vs. 0%, p = 0.02) [17]. In this chapter, we 
reviewed the epidemiology and possible predictors of epilepsy in each type of cere-
brovascular diseases. The characteristics of semiology and electroencephalography 
(EEG) findings which enable us to take early treatment strategy are summarized. 
Relevance of acute-symptomatic seizures and status epilepticus to epilepsy is also 
discussed.
2. What kinds of vascular lesions can cause epilepsy?
2.1 General risk factors of poststroke seizures and epilepsy
Cerebrovascular disease is the most common etiology of acute symptomatic 
seizures and secondary epilepsy in adults, accounting for approximately 11% of 
epilepsy diagnosis [18].
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All types of cerebrovascular diseases can cause early or late seizures. Among them, 
the common causes of epilepsy are cerebral infarction, intracerebral hemorrhage, and 
SAH (Table 1). As a genetic risk factor of PSE, the relationship between PSE and the 
ALDH2 (aldehyde dehydrogenase 2) rs671 polymorphism is known [48].
The risk factors for early seizures after stroke include intracerebral hemor-
rhage, cerebral infarction with hemorrhagic transformation, stroke severity, and 
 alcoholism [49].
The risk factors for PSE include cortical involvement (visual neglect, dyspha-
gia, field defect, and so on), stroke severity indies at presentation, including low 
Glasgow Coma Scale, incontinence, or poor Barthel Index, hemorrhagic lesions, 
young age (< 65 years), and stroke subtype, particularly total anterior circulation 
infarcts [11]. Abraira et al. pointed that NIHSS score more than 4 at the stroke 
presentation and post-stroke status epilepticus duration more than 16 hours might 
predict of PSE in patients with early-onset post-stroke status epilepticus [50].
2.2 Cerebral infarction
Cerebral infarction can occur at any age, with the greatest risk being during 
the first week after birth. In adults, about 70–85% of cerebrovascular diseases are 
ischemic. Etiological subtypes of cerebral infarction are classified according to the 
TOAST classification (Table 2) [51], the ASCOD phenotyping system [52], and the 
Causative Classification System [53]. Most cases of PSE are due to arterial ischemic 
stroke [54], accounting for up to 9% of incident cases of epilepsy [55].
In ASCOD, every patient should be graded using 5 categories: A (atheroscle-
rosis); S (small-vessel disease); C (cardiac pathology); O (other cause), and 
D (dissection) [52]. With the Causative Classification System classification of 
ischemic stroke etiology, ischemic stroke is classified as the following; large artery 
atherosclerosis, cardio-aortic embolism, small artery occlusion, other causes, and 
undetermined causes [53].
Early seizure Late seizure Epilepsy
Cerebral infarction 4.8% [6] 3.8% [6] 2.0–4.0% [5, 19–21]
Intracerebral hemorrhage 31% [22] 4.0–11.8% [23, 24] 8.1–13.5% [4, 25]
Subarachnoid hemorrhage Up to 20% [26] 2.0–5.5% [27] 3.1–25% [28–30],
Acute subdural hematomaa 24–36% [31–33] 42–44% [31–33] 58.3% [34]
Chronic subdural hematoma 3.6–42% [33] 1.6–30.7% [33, 35, 36] 4.3–6.9% [37, 38]
Acute epidural hematomaa 41% [39] 0% [39] 71.4% [34]
Cerebral venous thrombosis 34.0–46.7% 
[40–42]
11% [43] 5.2% [42]
Arteriovenous malformation 26.2%b [44] 26–35% [44] 67–72% [44]
Arteriovenous fistula NA NA 2.7%c [45]
Cavernous angioma NA NA 32.1%d [46]
Moyamoya disease NA NA 7.7% [47]
NA: not available.
aPost-traumatic seizure/epilepsy.




Prevalence of early seizure, late seizure, and epilepsy in each cerebrovascular disease.
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Early seizure occurrence is associated with hemorrhagic transformation and 
stroke severity. Late seizure is associated with cortical involvement and stroke 
severity [56]. The SeLECT score is proposed to predict the risk of late seizures after 
ischemic stroke, using only five well-defined parameters (Severity of stroke, Large-
artery atherosclerotic etiology, Early seizures, Cortical involvement, and Territory 
of middle cerebral artery involvement) [57]. The overall risk of late seizures was 4% 
at 1 year and 8% at 5 years after stroke. Based on the estimation, patients with the 
SeLECT value of 7 points or more have more than 60% risk of seizures within 5 years 
after stroke, which is higher than the practical definition of epilepsy by ILAE (at 
least 60% over the next 10 years) [9], even though the patients have no unprovoked 
seizures. The risk factors for epilepsy after ischemic stroke include early seizures, 
stroke severity, stroke subtype, stroke location (anterior circulation infarct and cor-
tical involvement), stroke recurrence, artery dissection and established coronary dis-
ease [56, 58]. Patients receiving thrombolytic or intra-arterial reperfusion therapies 
for acute ischemic stroke are at higher risk of epilepsy [59]. Post-stroke seizures can 
be sometimes associated with small vessel disease. The risk of developing seizures 
is more strongly related to the localization of lacunar infarctions in the hemispheric 
white matter (leukoaraiosis) than in the basal ganglia or in the brain stem [60]. 
Branch atheromatous disease could also have an association with late seizures [61].
2.3 Intracerebral hemorrhage
Early seizures were seen in 31% of patients with spontaneous intracerebral 
 hemorrhage who were evaluated with continuous electroencephalographic moni-
toring and over half had purely electrographic seizures only [22]. The incidence 
of PSE after intracerebral hemorrhage is between 8.1 and 13.5% [4, 25]. Seizures 
secondary to intracerebral hemorrhage are relatively common like this and likely 
underdiagnosed event that may have little impact on in-hospital mortality and 
morbidity [62]. Nonconvulsive electrographic seizures may be associated with 
hematoma expansion [22].
The risk factors for seizures following intracerebral hemorrhage are associated 
with hemorrhage volume, hemorrhage location within the cerebrum, cortical 
involvement and the severity of neurological deficits [10]. Surgery for an intracere-
bral hemorrhage is an additional risk for the development of late seizures [63].
For patients with spontaneous intracerebral hemorrhage, clinical early seizures 
should be treated with antiepileptic drugs [64]. When the patients have a change in 
mental status, the evaluation with EEG is recommended. If the patients have elec-




Stroke of other determined etiology
Stroke of undetermined etiology
a. Two or more causes identified
b. Negative evaluation
c. Incomplete evaluation
*Possible or probable depending on results of ancillary studies.
Table 2. 
The TOAST classification of subtypes of acute ischemic stroke [51].
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Current clinical guidelines do not recommend the routine use of prophylactic 
antiepileptic drugs for spontaneous intracerebral hemorrhage [64] because there is 
no evidence to improve neurological function [65].
Periodic discharges on EEG could be associated with cortical intracerebral 
hemorrhage and poor outcome [22].
2.4 Subarachnoid hemorrhage
Early seizures may be seen in up to 20% of patients after aneurysmal SAH, and 
more commonly in association with intracerebral hemorrhage, hypertension, and mid-
dle cerebral and anterior communicating artery aneurysms [26]. Early seizures after 
SAH occur most commonly in the first 24 hours [26]. The actuarial risk of epilepsy 
after SAH was 18% by the first year, 23% by the second year, and 25% by the fifth year 
in the survivors of SAH [28]. Aneurysm location most associated with the development 
of SAH-related epilepsy is middle cerebral artery at the M1 branch and artery bifurca-
tion [66]. The risk factors for epilepsy after aneurysmal SAH include the rupture of 
aneurysms in the anterior circulation, a young age, intracerebral hemorrhage, a poor 
neurological outcome, and hemosiderosis [29, 66]. Severe Hunt and Hess score as well 
as intraventricular hemorrhage elevate the risk of having a seizure after SAH [67]. The 
degree of neurological impairment and presence of an early seizure soon after the time 
of SAH have been identified as a risk factor for post-SAH epilepsy [68].
Nonconvulsive seizures following SAH cause transient brain hypoxia, increased 
intracranial pressure, and increased blood pressure [69]. Although evidence is not 
sufficient yet, guidelines recommend to consider the prophylactic use of antiepileptic 
medication except phenytoin (PHT) in the immediate post-hemorrhagic period and 
to consider the routine use of antiepileptic medication for patients with known risk 
factors for late seizures such as prior seizure, intracerebral hematoma, intractable 
hypertension, infarction, or aneurysm at the middle cerebral artery, though long-
term use is not recommended [26]. Importantly, PHT should be avoided for the 
prophylaxis of early seizure following aneurysmal SAH because of known association 
with vasospasm, worsening of cognitive outcomes, and infarctions [70]. Recently, 
levetiracetam (LEV) is increasingly used for the prophylaxis of early seizures [26, 70].
2.5 Cerebral venous thrombosis
In patients with cerebral venous thrombosis (CVT), early seizures were seen in 
6.9–76% [71], status epilepticus in 6% [40], late seizures in 11% [43], and post-CVT 
epilepsy in 4–16% [71]. Risk factors for early seizures following cerebral sinus 
thrombosis include brain parenchymal lesions, focal neurological deficits, supra-
tentorial parenchymal lesions, intracerebral hemorrhage, focal edema/ischemic 
infarction, superior sagittal sinus thrombosis, cortical venous thrombosis, and 
pregnancy/puerperium [72–77]. Known risk factors for late seizures after CVT are 
early seizures, baseline intracerebral hemorrhage, decompressive hemicraniec-
tomy, sigmoid sinus thrombosis, loss of consciousness at presentation, and genetic 
thrombophilia [43, 75, 78].
In the absence of previous early seizure following cerebral venous thrombosis, 
there is no evidence to prescribe prophylactic antiepileptic drugs during acute phase 
[40]. European and American guidelines recommend antiepileptic drug treat-
ment on CVT for patients with early seizures and supratentorial lesions in order to 
prevent further seizures [79, 80].
Due to the high recurrence risk of late seizures, epilepsy diagnosis and com-
mencement of antiepileptic drugs following a first late seizure after CVT is 
 reasonable [43].
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3. How vascular lesions acquire epileptogenicity?
3.1 Epileptogenicity
Epileptogenicity is the development and extension of tissue capable of generat-
ing spontaneous seizures, resulting in the development of an epileptic disorder or 
progression after the disorder is established [81]. In general, there are three phases 
to acquire epileptogenicity. First, brain-damaging insult (stroke, traumatic brain 
injury and central nervous system infections etc.) occurs (acute phase). Second, 
brain acquires epileptogenicity during a certain period of time (latent period), and 
third, as a result spontaneous recurrent seizures occur (chronic phase). In order to 
elucidate the mechanism of acquiring epileptogenicity, it is very important to study 
what occurs in the brain during latent period.
Risk factors, especially relevant to clinical practice, for acquiring epileptogenic-
ity and subsequent development of PSE are summarized in Table 3.
PSE: post-stroke epilepsy, PET: positron emission tomography.
Animal experiment of stroke model is very helpful to elucidate epileptogenicity. 
Several studies directly evaluate neuronal and glial activities after stroke by using 
electrophysiological and histological measures. Early seizures evoked by traumatic 
brain injury and stroke can be suppressed by short-term prophylactic administra-
tion of antiepileptic drugs but it doesn’t alter the incidence of PSE [83]. Therefore, 
targeting only neurons may be insufficient to prevent epileptogenicity; the glial 
involvement in the process of epileptogenesis after experimental stroke should be 
reviewed. Changes in neuro-glial syncytium during the course of acquiring epilep-
togenesis are shown in Figure 1.
Astrocytes form extensive gap junctions composed of connexin (Cx) 43 with 
other astrocytes and play a central role of neuron–glia syncytium [84]. Astrocyte 
regulates neural activities by removing excessive extracellular potassium at syn-
apses and transports them into regions of low potassium concentration via gap 
junction [85]. Cx 43 also forms hemichannels in the astrocyte. Hemichannels 
allow the exchange of ions and molecules between the cytoplasm and the 
Symptom 
severity
Clinical stroke severity is a major factor in the development of PSE
Lesion size Post-stroke seizures were more likely to develop in patients with larger lesions involving 
multiple lobes of the brain than in those with single lobar involvement
Total anterior circulation infarct is a particularly strong risk factor for PSE compared with 
other ischemic stroke subtypes
Lesion 
location
Extent of cortical involvement is a significant risk factor for PSE
Involvement of the parieto-temporal cortex, supramarginal gyrus, and superior temporal 
gyrus associates with post-stroke epileptogenesis
Stroke 
subtype
PSE occurred more frequently with hemorrhagic stroke than with ischemic stroke, with 




A PET study revealed reduced cortical blood flow and oxygen consumption are related to 
late-onset epilepsy in patients with leukoaraiosis
Vascular risk 
factors
Vascular risk factors including history of myocardial infarction, peripheral vascular 
disease, hypertension, total serum cholesterol, and left ventricular hypertrophy, are 
associated with PSE
Other factors Genetic factors, peri-injury exposome, etc.
Table 3. 
Risk factors for acquiring epileptogenicity after stroke [7, 10, 25, 31, 32, 82].
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extracellular medium, which physiologically regulate neuronal activity as well 
as synaptic strength and plasticity [86] and also pathologically be activated by 
 inflammation [87].
3.2 Acute phase
Epileptiform activities after middle cerebral artery (MCA) occlusion were first 
recorded using surface conventional EEG in the rat experiment by Hartings et al. 
[88]. 55–90% of animals had epileptiform activities 33–50 minutes after stroke 
which exacerbated brain injury [89–91]. High frequency oscillations (HFOs) are 
involved with epileptogenic region in intractable epileptic patients (e.g. focal 
Figure 1. 
Neuro-glial syncytium in the course of acquiring epileptogenesis. (A) Physiological state. A neuron generates 
physi0logical action potentials in neuro-glial syncytium. As a result of neural firing, extracellular potassium 
concentration is elevated. Kir 4.1 channels in the astrocyte mediate spatial potassium burring and regulates 
neural activities by transporting them into regions of low potassium concentration such as blood vessels. (B) 
Acute phase. In the acute phase of ischemic stroke, ischemic changes of neuron and glia gradually appear in 
the ischemic lesion. Neurons and astrocyte/microglia cells in the peri-ischemic lesion are activated. Activated 
microglia called M1 secretes cytokines (e.g. TNF-α, IL-1β), which in turn inhibit gap junctional communication 
and increase hemichannel activity in astrocytes. The release of molecules, such as ATP and glutamate, damages 
adjacent neurons and glia cells. Inhibition of gap junction leads to dysfunction of spatial potassium buffering, 
which further provokes neural firing. Electrophysiologically, neuronal activities lead to increase of spatial 
potassium, and DC shifts appear as a result of exceeding the capacity of buffering. (C) Latent period. Necrotic 
region in the ischemic lesion is cleaned by microglia and gliosis occurs in per-ischemic lesion. Inflammation, 
mainly caused by M1 phenotype, continues in this period and further damages neurons and astrocytes. (D) 
Chronic phase. In the chronic phase of ischemic stroke, inflammation subsides, and epileptogenicity is acquired. 
Ischemic lesion is replaced by fibrillary astrocyte and peri-ischemic lesion is occupied by gliosis. Dysfunction 
of neuro-glial syncytium reaches the pathological state which generates spontaneous epileptic activities. 
Electrophysiologically, DC shifts precede neural firing. N: neuron, A: astrocyte, M: microglia, TNF-α : tumor 
necrosis factor-alpha, IL-1β: interleukin 1 beta, ATP: adenosine triphosphate, DC: direct current, Cx43: 
connexin 43.
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cortical dysplasia) and rat pilocarpine model of temporal lobe epilepsy [92]. In rat 
stroke model, HFOs were also observed 5–15 seconds before run of theta activities 
consisted of sharp positive spikes followed by longer negative waves and terminated 
at the onset of the discharge after ischemia [93]. Direct current (DC) shifts are 
associated with a steady increase of the extracellular potassium concentration, 
which matches to the intracellular voltage variations of glial cells [94]. In rat MCA 
occlusion model, a highly significant linear correlation is reported between the 
number of depolarization and the infarct size at peri-infarct region, and DC shifts 
are also recorded [95], which may indicate exceeding of potassium concentration to 
the buffering capacity of astrocyte.
Histological changes immediately after stroke are reported by Ramírez-Sánchez 
et al. [96]. When rats were subjected to 90 minutes MCA occlusion followed by 
23 hours of reperfusion, neuronal cells in the peri-infart cortex, cornu ammonis 
(CA) 1, and dentate gyrus (DG) areas were decreased, and widespread reactive 
astrogliosis in both of the cortex and the hippocampus (CA1, CA3, and DG areas) 
was observed 24 hours after ischemia.
Therefore, in acute phase of epileptogenesis, stroke immediately damages 
neurons and glia cells, and provokes neuronal epileptic activity. Furthermore, as a 
result of destruction of cells and excessive neural firing, the extracellular potassium 
concentration increases beyond glial potassium buffering capacity, which may lead 
to a vicious circle of further neural firing.
3.3 Latent period and chronic phase
Chronic phase of the aged rat post-stroke brain is reported by Titova et al. [97]. 
They evaluated ischemic lesions at 28 days induced by 5o minutes right MCA occlu-
sion in aged rat (18 month-old). In ischemic lesion, extensive glial scar and apop-
totic neurons were found and phagocytic macrophages/microglia cells were seen 
in the peri-lesional rim. The brain irradiation possibly affects normal post-stroke 
microglia signaling and prevents following activation of inflammatory cascade 
mechanisms [98]. When proton irradiation was performed at the heads of aged 
rat ten days prior to right MCA occlusion, chronic phagocytosis and T-lymphocyte 
infiltration in the brain were reduced, and formation of glio-vascular complexes, 
neuronal viability, neovascularization were improved in the peri-lesional zone, and 
neurological severity scoring were improved [97]. These data clearly demonstrated 
that, in addition to direct damage to brain by stroke itself, subsequent inflammation 
also damages neuron, astrocyte, vessel and neural function.
In the central nervous system, microglia is a major player in the brain inflam-
mation. Stroke activates microglia which is called M1 phenotype, which secretes 
inflammatory cytokine like interleukin (IL) and tumor necrosis factor (TNF)-α 
[99]. Astrocyte also secretes inflammatory cytokines (e.g. TNF-α, IL-1β) via 
Cx43-hemichannel in the MCA occlusion model [100], whereas Gap19, a selective 
Cx43-hemichannel inhibitor, exhibits neuroprotective effects on cerebral ischemia/
reperfusion via suppression of the expression of Cx43 and toll-like receptor 4 
pathway-relevant proteins, and prevention of the overexpression of TNF-α and 
IL-1β in astrocyte. An obvious improvement in neurological scores and infarct vol-
ume reduction were observed in Gap19-treated mice after brain ischemia induced 
by MCA occlusion [100].
Inflammatory cytokines, specifically IL-1β and TNF-α, are involved in inhibition 
of gap junctional communication and increase of hemichannel activity in astrocytes 
[87]. Inhibition of gap junction communication impedes potassium buffering 
which promotes neural firing. Increased hemichannel activity allows the release 
of molecules such as adenosine triphosphate, glutamate, nicotinamide adenine 
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dinucleotide, glutathione, and prostaglangin E2 [101–105]. These molecules are 
toxic to adjacent cells and finally lead to neuronal and glial death [106, 107]. These 
insults to the central nervous system tissue trigger a range of molecular, morpho-
logical, and functional changes of astrocytes called reactive gliosis [108], which is 
one of the most important pathogenic steps of spontaneous seizure [92].
As for electrophysiological study of PSE model, few data are available because 
only 10–20% of post-stroke rats develop spontaneous seizure [109]. Brain dam-
age induced by brain injury, axotomy, or toxic substance in addition to stroke also 
activates microglia [99], therefore, electrophysiological pathology induced by 
inflammation of other causes is probably plausible as that is induced by stroke. 
The mechanism of epileptogenesis after status epilepticus model is well studied. 
Pilocarpine, a muscarinic acetylcholine agonist, induces status epilepticus, and 
after a certain latent period surviving rats acquire epileptogenesis [110]. This rat 
model also shows HFOs and DC shifts during seizure at acute phase [92]. Gliosis 
occurs in 8–12 weeks after pilocarpine injection [111], and spatial potassium buffer-
ing function at hippocampus is impaired [112]. EEG recording during epileptic 
seizures at chronic phase of this model rat showed DC shifts preceding HFOs and 
conventional ictal EEG patterns, which may be the result of dysfunction of astro-
cyte extracellular potassium buffering [92]. Minocycline is a second-generation 
tetracycline and has potent anti-inflammatory effects independent of its antimi-
crobial action. Minocycline attenuates spontaneous recurrent seizures following 
pilocarpine-induced status epilepticus, and inhibits the status epilepticus-induced 
microglial activation and overproduction of IL-1β and TNF-α in the hippocampal 
CA1 and the adjacent cortex, without affecting astrocyte activation. In addition, 
minocycline prevents the status epilepticus-induced neuronal loss [113].
4.  Neurological examination, electroencephalography, and imaging 
findings
4.1 Neurological examination
Post-stroke epilepsy is common among the elderly. Nonconvulsive seizures 
are common in elderly patient with epilepsy, and clinical presentation of elderly 
patients with epilepsy differs considerably from younger patients; less common and 
nonspecific auras (e.g. dizziness); less frequent automatisms; prolonged post-ictal 
confusion; common complaints with altered mental status, confusion, and memory 
disturbance [114].
These characteristics hinder and delay the diagnosis of epilepsy in the elderly. 
Co-morbid diseases such as hypertension, dementia, transient ischemic attack 
(TIA), and cardiac diseases can mislead to attribute these symptoms as one of the 
manifestations of pre-existing conditions in an elderly patient with new-onset 
epilepsy [114]. It is necessary and important, for example, to evaluate stroke or 
TIA immediately for patient with new-onset motor aphasia with brain imaging 
examinations; however, the symptom can be of aphasic seizures per se or in associa-
tion with various neurological emergencies, especially if the duration of aphasia is 
brief, severity of aphasia is fluctuating, or other concomitant neurological findings 
exist. Clinical presentation of elderly patients with new-onset epilepsy is commonly 
nonspecific, and thus, EEG should be utilized for the diagnosis of epilepsy in the 
elderly.
Status epilepticus occurs in 9–19% of patients with post-stroke seizures, while 
status epilepticus following stroke accounted for 14–27% of all status epilepticus 
in adults [115]. Tomari et al. reported that 24% of post-stroke seizures with status 
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epilepticus are nonconvulsive status epilepticus [115]. The initiation of treat-
ments for nonconvulsive status epilepticus is commonly delayed compared with 
convulsive status epilepticus because the diagnosis is often difficult without EEG. 
The evaluation with EEG is mandatory for patients with nonspecific symptoms 
such as depressed level of consciousness. Subtle neurological manifestations (e.g. 
myoclonus, rigidity/spasticity, saccadic eye movement, eye/head turning, abnormal 
reflexes), their fluctuation, and repetitions of their combination (e.g. myoclonus - > 
rigidity/spasticity - > paresis - > hyperreflexia, tachypnea - > eyelid twitch - >  
eye open - > pupil dilation - > eye/head turning) are worthwhile to further evalua-
tion for status epilepticus.
4.2 Electroencephalography
Epileptiform discharges (spikes and sharp waves) in conventional EEG are 
highly specific to seizure recurrence but not sensitive enough in adult patients (sen-
sitivity 17.3%, specificity 94.7%) [116]. Therefore, lack of epileptiform discharges 
does not simply exclude the possibility of epileptic seizures. Other nonspecific find-
ings represent both neuronal damage and epileptic activities; amplitude decrease of 
background activities (e.g. posterior dominant rhythm, fast waves, sleep spindles) 
and presence of focal slow activities should be serially evaluated.
Recently, long-term, continuous EEG monitoring with video record is increas-
ingly utilized in intensive care unit for early diagnosis of nonconvulsive status 
epilepticus. Besides conventional EEG seizure patterns (i.e. rhythmic activities with 
evolution in frequency and amplitude), lateralized periodic discharges, evolving/
fluctuating activities, and abnormal rhythmic fast activities superimposed to rhyth-
mic/periodic activities should be evaluated [117–119]. The Salzburg EEG criteria 
for diagnosis of nonconvulsive status epilepticus include improvement of EEG after 
intravenous antiepileptic drugs [120].
4.3 Brain imaging
Brain computer tomography is a well-established measure to evaluate intracra-
nial hemorrhage, edema, and mass lesions, and has been utilized for deciding the 
indication of thrombolytic therapy in acute ischemic stroke.
Initial use of brain magnetic resonance imaging is useful not only to detect 
cerebrovascular disorders and other neurological conditions but also to evaluate 
seizure foci and spread of seizures via neural network. Hyperintensity of diffusion-
weighted imaging especially in the cortex and hyperperfusion of arterial spin label-
ing can help early diagnosis of nonconvulsive status epilepticus [118, 119, 121, 122].
5. Treatment strategy: adults in general, and in elderly
5.1 Prevention of post-stroke seizures and epilepsy
The prevalence of post-stroke early seizure is high; 4.8% for ischemic stroke and 
7.9% for hemorrhagic stroke [5]. Current clinical guidelines recommend against 
the routine use of prophylactic antiepileptic drugs for spontaneous intracerebral 
hemorrhage [64], because primary prevention of seizures with antiepileptic drugs 
does not improve neurological function during follow up (up to 90 days) [65]. For 
SAH, guidelines state that a short course (3 to 7 days) of prophylaxis with antiepi-
leptic drugs may be started in the immediate post-bleeding period, although this 
prophylaxis has a low level of evidence [70]. PHT, which can cause worse cognitive 
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outcomes, vasospasm, and infarctions, should be avoided to use for prophylaxis 
after SAH, and LEV is increasingly being used [70].
The prevalence of post-stroke late seizure is 3.8% for ischemic stroke and 2.6% 
for hemorrhagic stroke [5]. As the risk of recurrence after a first unprovoked late 
seizure can be as high as 71.5% over the next 10 years, the occurrence of a single late 
post-stroke seizure is consistent with a diagnosis of epilepsy. The risk factors for 
seizures after ischemic stroke were cortical involvement of infarction and stroke 
disability. For hemorrhagic stroke, the risk factor of seizures was cortical location. 
The risk factors in general for post-stroke early seizures during the first 48 hours 
include advanced age, confusional syndrome, hemorrhagic stroke, large lesions, 
involvement of parietal and temporal lobes, and occurrence of neurologic and 
medical complications [6].
None of the currently available antiepileptic medication has been shown to 
prevent PSE [123–125]. Immediate initiation of continuous antiepileptic medication 
treatment of the first early seizure after cerebral infarctions decreased the risk of 
recurrent seizure during the first 2 years but has no influence on the development of 
recurrent seizures after discontinuing antiepileptic medication in 2 years [124].
As mentioned in Chapter 4, anti-inflammatory therapy is the most expected 
strategy in order to prevent epileptogenesis. Statins, 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol 
reduction, may also be beneficial in the treatment of inflammatory diseases. In 
animal experiment, atorvastatin reverses paralysis in central nervous system auto-
immune disease via suppressing secretion of type 1 helper T cell (Th1) cytokines 
(IL-2, IL-12, interferon-Γ, and TNF-α) and promoting secretion of Th2 cytokines 
(IL-4, IL-5 and IL-10) and transform of growth factor-β, in Th1-mediated central 
nervous system demyelinating disease model of multiple sclerosis [126]. In patients 
with epilepsy, statin use, especially in the acute phase of ischemic stroke, may 
reduce the risk of post-stroke early-onset seizures [127]. Adequate statin treatment 
after ischemic stroke may lower the risk of PSE [128].
In the future, periodic measurement of inflammatory biomarker in the stroke 
patients having the risk factors as mentioned above and evaluation of the effect of 
anti-inflammatory agents such as statin to epileptogenicity are warranted.
5.2 Treatment of post-stroke seizures and epilepsy
The decision to initiate antiepileptic medication treatment after a first unpro-
voked seizure should be individualized and based on age, preference of a patient, 
and clinical, legal, and socio-cultural factors [129]. Upon commencement of treat-
ment with antiepileptic medication, monotherapy is recommended, among various 
kinds of antiepileptic medication available. For patients with PSE especially with 
cerebral infarction, possible adverse event of lipid abnormalities should be avoided 
to prevent recurrent stroke. High tolerability, which is associated with minimum 
side effects such as sleepiness or dizziness, is important in elderly patients in terms 
of safety against falling as well as adherence improvement. In addition, drug inter-
action is a matter of concern in patients undergoing polypharmacy.
Patients who are treated with enzyme-inducing antiepileptic drugs such as 
carbamazepine (CBZ), PHT, and phenobarbital (PB) show higher levels of total 
cholesterol, triglycerides and LDL-cholesterol, although the effects of valproate 
(VPA) on lipid profiles remain unclear [130]. On the other hand, patients who are 
treated with enzyme-inhibiting antiepileptic drugs and non-enzyme-inducing 
antiepileptic drugs are not significantly affected their lipid profile, whereas several 
reports showed LEV could be associated with higher LDL-cholesterol levels [130]. 
Due to the side effects of antiepileptic drugs, treatment with non-enzyme-inducing 
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antiepileptic drugs such as lamotrigine (LTG) and LEV is a reasonable treatment 
strategy in terms of lipid control [130]. In post-stroke seizures and epilepsy, LEV 
and LTG show higher tolerability than controlled-release CBZ [131].
Weight gain and obesity are associated with hypertension and atherosclerosis. 
It is well known that VPA, CBZ, PHT, gabapentin, vigabatrin, and pregabalin are 
associated with weight gain [132–134] while LTG and LEV are not [135, 136], and 
felbamate, topiramate (TPM), and zonisamide cause weight loss [137, 138].
Carotid-artery intima media thickness (CA-IMT) is an early marker of cerebral 
atherosclerosis [139]. The old-generation antiepileptic drugs such as CBZ, PHT 
and VPA are associated with significant increase of CA-IMT in adult patients with 
epilepsy [139, 140]. On the other hand, the new-generation antiepileptic drugs such 
as LTG and oxcarbazepine (OXC) have no effects on CA-IMT in adults and children 
[140, 141].
Hyperhomocysteinemia is an independent risk factor for stroke [142]. OXC, 
TPM, CBZ, and PB are associated with higher plasma total homocysteine level; 
adult epilepsy patients treated with LTG and LEV as monotherapy had normal total 
homocysteine level [143].
Currently, patients with PSE are rarely underwent pre-surgical evaluation even 
though their seizures are intractable. Good seizure outcome is reported in young 
generation under 50 years old whose epilepsy onset is at age 20 years or younger, 
who underwent tailored hemispherectomy based on the findings of stereoelectro-
encephalography recordings [144]. Approximately 3% of patients with cerebral 
dural arteriovenous fistula experience seizures [45]. Although status epilepticus 
is not common among patients with cerebral dural arteriovenous fistula, there is a 
case report that endovascular intervention improved the seizure control of patients 
with cerebral dural arteriovenous fistula who present with status epilepticus [145].
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